Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Primer group for detecting nucleic acid of central nervous infection pathogen, product and application

A central nervous system and pathogen technology, applied in the biological field, can solve the problem of incomplete pathogens, achieve high sensitivity, high accuracy, and shorten the detection cycle

Pending Publication Date: 2022-06-28
SIMCERE DIAGNOSTICS CO LTD +2
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are few products on the market to detect the nucleic acid of pathogens of central nervous system infection, and the coverage of pathogens is not complete.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Primer group for detecting nucleic acid of central nervous infection pathogen, product and application
  • Primer group for detecting nucleic acid of central nervous infection pathogen, product and application
  • Primer group for detecting nucleic acid of central nervous infection pathogen, product and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0078] Embodiment 1 The application reaction system is established

[0079] By culturing and analyzing the central nervous system infection samples, the pathogen types of such infected samples are determined. HSV-1), herpes simplex virus 2 (Herpes simplex virus 2, HSV-2), varicella zoster virus (VZV), cytomegalovirus (Cytomegalovirus, CMV), human herpes virus type 6 (Human herpesvirus 6, HHV-6), Epstein-Barr virus (EBV), mumps virus (Mumps virus, MuV), human parechovirus (Human parechovirus, HPeV)), bacteria (Escherichia coli, E. coli), Listeria monocytogenes (Listeria monocytogenes, LM), Neisseria meningitidis (Neisseria meningitidis, NM), Streptococcus agalactiae (Streptococcusagalactiae, GBS), Streptococcus pneumoniae (Streptococcus pneumoniae, SP), Haemophilus influenzae (Hi), Mycobacterium tuberculosis (MTB)), fungi (Cryptococcus neoformans (CN)), mycoplasma pneumonia (MP).

[0080] Further, in this example, by exploring the specific genes of each detection pathogenic i...

Embodiment 2

[0128] Example 2 Confirmation of the minimum detection limit of the application

[0129] After confirming the optimal reaction system in this example, each detection index is used for the minimum detection limit confirmation test using the plasmid synthesized by Sangon Bioengineering (Shanghai) Co., Ltd. designed according to the specific detection gene. The verification scheme is as follows:

[0130]The plasmids with known concentrations of each indicator were diluted to three gradients of 50copies / μL, 10copies / μL, and 5copies / μL, and each gradient was detected twice; the lowest concentration that could be detected 100% was taken as the lowest detection limit of each indicator. , and then at this concentration, repeat the detection 5 times, and all 5 times are detected, then the concentration can be determined as the minimum detection limit of the indicator. The specific verification process is as follows: first, the amplification primer MIX and the extension primer MIX are ...

Embodiment 3

[0133] Example 3 Clinical sample detection

[0134] In the process of system optimization in this embodiment, each detection site has at least one clinical sample for detection and verification to confirm that the detection results in this embodiment are accurate. In this example, after confirming the optimal reaction system, a series of verification experiments, including accuracy and precision experiments, were carried out. The specific verification scheme is as follows:

[0135] (1) Accuracy experimental verification scheme: 18 test indicators were selected from a clinical sample for verification, and the mass spectrometry test results were more than 95% consistent with the theoretical results, and the verification passed.

[0136] (2) Validation scheme of precision experiment: Pick 5 clinical samples, and test each sample 3 times, and test 2 batches in total. If the consistency of precision between batches is greater than 95%, the verification is passed.

[0137] The spe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
conversion efficiencyaaaaaaaaaa
Login to View More

Abstract

The invention relates to the technical field of biology, and particularly provides a primer group for detecting nucleic acid of a central nervous infection pathogen, a product and application, and the primer group and the product can be used for simultaneously detecting nucleic acid of 18 common pathogenic microorganisms of central nervous infection on a time-of-flight mass spectrometry platform by utilizing a multiple system; meanwhile, multiple system detection of DNA and RNA is realized, the detection cost is greatly reduced, the detection time is shortened, and timely and accurate diagnosis and treatment basis is provided for clinic.

Description

technical field [0001] The present application relates to the field of biotechnology, in particular to a primer set, product and application related to nucleic acid detection of central nervous system infection pathogens. Background technique [0002] Central nervous system infection refers to acute or chronic inflammatory (or Non-inflammatory) diseases, including encephalitis, meningitis, meningoencephalitis, encephalomyelitis, brain abscess, etc., have the characteristics of high fatality and disability rate. [0003] According to the 2015 Global Burden of Disease Study data published in the journal Lancet Neurology in 2017, meningitis ranked third in both disability-adjusted life years and mortality in terms of disease burden. With the improvement of public health conditions and the advancement of medical technology, the mortality rate of meningitis has been significantly reduced, but the incidence rate has increased significantly. In 1996, there were 403,000 cases of me...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/70C12Q1/6895C12Q1/689C12Q1/686C12Q1/14C12Q1/10C12Q1/04C12N15/11
CPCC12Q1/705C12Q1/701C12Q1/6895C12Q1/689C12Q1/686C12Q2600/16C12Q2600/166C12Q2533/101C12Q2537/143C12Q2565/627C12Q2545/101
Inventor 王利顾馨仪郑诗雨郭涛胥慧李诗濛任用
Owner SIMCERE DIAGNOSTICS CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com